A Multicentre, Multinational, Parallel Group, Observer-blind, Randomised, Placebo-controlled Study on the Group B Streptococcus Vaccine (GBS-NN/NN2), Investigating the Immunogenicity and Safety of Four Vaccination Regimens in Pregnant Woman, Assessing IgG Specific to AlpN Proteins in Cord Blood and Maternal Blood, and the Safety Profile in Mother and Infant up to 6 Months Post-delivery
Latest Information Update: 18 Nov 2024
Price :
$35 *
At a glance
- Drugs GBS NN (Primary)
- Indications Streptococcal infections
- Focus Pharmacodynamics
- Sponsors Minervax
- 27 Mar 2024 Status changed from active, no longer recruiting to completed.
- 08 Dec 2023 This trial has been completed in Denmark (Date of the global end of the trial: 18-Oct-2023), according to the European Clinical Trials Database record.
- 10 Jan 2023 Planned End Date changed from 1 Jul 2023 to 1 Nov 2023.